```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *
* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:19:56 ON 11 DEC 2007

=> file reg
=> Uploading C:\Program Files\Stnexp\Queries\Queries\10595798a.str
```




```
chain nodes :
11  12  13  14  15  16  17  18  19
ring nodes :
1  2  3  4  5  6  7  8  9  10
chain bonds :
7-11  9-19  11-12  11-18  11-17  12-13  13-14  14-15  15-16
ring bonds :
1-2  1-6  2-3  3-4  4-5  4-7  5-6  5-10  7-8  8-9  9-10
exact/norm bonds :
1-2  1-6  2-3  3-4  4-5  4-7  5-6  5-10  7-8  7-11  8-9  9-10  9-19  11-12  11-18
11-17  12-13  13-14  14-15  15-16


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:Atom  17:CLASS  18:CLASS
19:Atom



L1      STRUCTURE UPLOADED

=> s l1 sam
L2            3 SEA SSS SAM L1

=> s l1 full
L3          146 SEA SSS FUL L1

=> file caplus

=> s l3
L4            2 L3

=> s l4 and pd< nov 2003
      23873125 PD< NOV 2003
                 (PD<20031100)
L5            0 L4 AND PD< NOV 2003
```

=> dis l4 1-2 bib abs fhitstr

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:523425 CAPLUS Full-text
DN 143:59843
TI Preparation of 5-aminosulfonyl-7-phenylisoquinolines as inhibitors of protein kinase B (Akt1).
IN Barda, David Anthony; Henry, Kenneth James, Jr.; Huang, Jianping; Joseph, Sajan; Lin, Ho-Shen; Richett, Michael Enrico
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005054202	A1	20050616	WO 2004-US37189	20041122
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1689719	A1	20060816	EP 2004-820010	20041122
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	US 2007037796	A1	20070215	US 2006-595798	20060512
PRAI	US 2003-524963P	P	20031125		
	WO 2004-US37189	W	20041122		

OS MARPAT 143:59843
GI



I

AB Title compds. [I; R1 = H, halo, OH, amino, CHF2, CF3, NHSO2Me; R2-R4 = H, halo, alkyl, CF3, amino, NO2, SMe, morpholino, (substituted) piperazinyl, pyrrolidinyl, diazepinyl, Ph, piperidinyl, etc.; R2R3 = atoms to form a benzo ring; R5, R6, R8 = H; R7, R9 = H, OH], were prepared as anticancer drugs (no data). Thus, 7-phenylisoquinoline-5-sulfonic acid (2-aminoethyl)amide (preparation given) and 3-naphthalen-1-ylpropionaldehyde were stirred 6 h in ClCH2CH2Cl; Na triacetoxyborohydride was added followed by stirring overnight

to give 7-phenylisoquinoline-5-sulfonic acid [2-(3-naphthalen-1-ylpropylamino)ethyl]amide.

IT 854689-39-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of aminosulfonylphenylisoquinolines as inhibitors of protein kinase B)

RN 854689-39-7 CAPLUS

CN 5-Isoquinolinesulfonamide, N-[2-[[3-(4-nitrophenyl)propyl]amino]ethyl]-7-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:927179 CAPLUS Full-text
DN 141:395430
TI Preparation of isoquinoline-5-sulfonic acid amides as inhibitors of Akt (Protein kinase B) for treating neoplasms and viral infections
IN Al Awar, Rima Salim; Barda, David Anthony; Henry, Kenneth James, Jr.; Joseph, Sajan; Lin, Ho-Shen; Lopez, Jose Eduardo; Richett, Michael Enrico; Somoza, Carmen
PA Eli Lilly and Company, USA; Dee, Albert Gerard
SO PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004094386	A1	20041104	WO 2004-US6093	20040325

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,

	BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004232682	A1	20041104	AU 2004-232682	20040325
	CA 2518180	A1	20041104	CA 2004-2518180	20040325
	EP 1611105	A1	20060104	EP 2004-723447	20040325
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004008353	A	20060321	BR 2004-8353	20040325
	CN 1768040	A	20060503	CN 2004-80008515	20040325
	JP 2006521382	T	20060921	JP 2006-508921	20040325
	US 2007043040	A1	20070222	US 2004-547969	20040325
	IN 2005KN01724	A	20070622	IN 2005-KN1724	20050830
PRAI	US 2003-458988P	P	20030328		
	WO 2004-US6093	A	20040325		

OS MARPAT 141:395430

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1 = H, halo, NH2, OH; R2 = H, alkenyl, (un)substituted alkyl; R3 = H, alkyl; R4 = H, halo, alkyl, alkoxy; R5 = H, halo, alkyl, alkoxy, CF3, NO2; or R4CCR5 = benzo-fused ring; R6 = H, halo, alkoxy, CF3, NO2, CN, cycloalkyl, OPh, phenethyl, isoxazolyl, furyl, methylsulfonyl, (un)substituted alkyl, Ph, thienyl, benzyl, benzoyl; Y = (CH2)n; n = 2-3; X = O, S(O)p, NH and derivs.; p = 0-2] were prepared as inhibitors of AKT activity. For example, DIBAL-H reduction of [4-bromo-2-(isoxazol-5-yl)phenoxy]acetic acid Me ester (preparation given) and reductive amination with isoquinoline-5-sulfonic acid (2-aminoethyl)amide gave amine II. I had IC50 values ≤ 2 μM in an Akt1 phosphorylation assay. Thus, I are useful for the treatment of susceptible neoplasms and viral infections.

IT 787576-27-6P, 7-(3-Hydroxyphenyl)isoquinoline-5-sulfonic acid [2-[[3-(2-benzyl-4-chlorophenoxy)propyl][bis(4-methoxyphenyl)methyl]amino]ethyl]amide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of isoquinoline-5-sulfonic acid amides as Protein
kinase B inhibitors for treating neoplasms and viral infections)

RN 787576-27-6 CAPLUS

CN 5-Isoquinolinesulfonamide, N-[2-[[bis(4-methoxyphenyl)methyl][3-[4-chloro-2-(phenylmethyl)phenoxy]propyl]amino]ethyl]-7-(3-hydroxyphenyl)- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y
STN INTERNATIONAL LOGOFF AT 13:21:39 ON 11 DEC 2007